

UNIVERSITY OF CALIFORNIA
SAN FRANCISCO MEDICAL CENTER

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO



SANTA BARBARA • SANTA CRUZ

UNIVERSITY OF CALIFORNIA HOSPITALS

SAN FRANCISCO, CALIFORNIA 94122

Child Study Unit, 546-C
Department of Pediatrics
January 9, 1970

Ronald S. Lipman, Ph.D.
Chief, Clinical Studies Section
Psychopharmacology Research Branch
National Institute of Mental Health
5454 Wisconsin Avenue
Chevy Chase, Maryland 20015

Dear Ron,

Enclosed is a summary of my report on side effects to which I have added from material gratefully received from Barbara Fish and Rachel Gittelman-Klein. I will need assistance from Keith regarding the rating scales for behavioral side effects since there would seem to be much overlap with target symptoms. It may be that the same behavioral rating forms for parents and teachers can cover both? The same question comes up relative to baseline determinations of child, parent, and teacher's attitude and role.

During lunch at our November meeting, one of your young colleagues whose name I can't remember (he has been doing some studies in San Francisco) mentioned a study he had made of physician's attitudes and suggested his studies and forms might be useful to this project. Could you please send me his name or any material he may have available?

I am also enclosing a questionnaire we used in a follow-up study of children with delayed language development. It may be of some use in formulating the history form. We find parents have great difficulty remembering ages for developmental milestones but do remember differences from siblings relative to development and behavior. In our study, even though these parents had been very concerned about the child's speech development, the majority of them were unable to remember when the child said his first word, phrases, or short sentences but could remember whether these were earlier or later compared to siblings.

On any of the summary
I will welcome comments from any of the group, particularly regarding item B-7 of my summary. I would also welcome suggestions regarding the physical side effects list--what items might be eliminated or left for the "others" category and what items should be added, and comments regarding which rating scales (see page 7) need to be devised.

Sincerely,

Helen Gofman
Helen Gofman, M.D.
Director, Child Study Unit
Associate Professor in Pediatrics

Encls.

HG:jmn

Pediatric Psychopharmacology Conference
November 13-14, 1969 N.I.M.H. Bethesda, Maryland

Report on Treatment Emergent Symptoms (Side effects)

Helen Gofman, M.D.

Attitudes

The following items should be considered in any study of effects (desirable or nondesirable) of psychotropic medications in children. Many of the factors that may influence the reports of drug response will also influence the reporting of side effects. Base line information and ongoing assessment re these factors is essential in planning this study and in devising rating sheets to evaluate the target symptoms as well as side effects.

A. Is the prescribed medication being taken by the child?

Tests are needed to ascertain the dosage actually being taken. Ideally blood levels or urine levels might give most reliable information. For many studies this may not be possible. Rating sheets should be devised for base line and regular assessment of dosage taken and the following should be considered in their construction:

1. Can the child take the medication or placebo in the form prescribed? An actual demonstration might be required.

2. Note amount of medication missing from the bottle on each visit.

3. Assume that some of the doses will be missed and devise questions that imply permission for these lapses in order to ascertain as accurately as possible the amount given as the study proceeds.

4. Determine who gives the child the medication. Is it the individual being questioned at repeated evaluations of the child? Is it the same individual consistently during the day or week--or many different adults who may prejudice the study by their bias (unknown to the investigator) or by poor reliability.

5. Are other medications being taken that are not part of the study?

6. Interval illness, infection or injury (more common with children) may influence side effects and target symptoms, the use of other medication, and/or the discontinuance of the prescribed medication.

Baseline assessments of attitudes of those participating in the study will be important in the total evaluation of results. These individuals include the child, his parent or caretakers, physicians, teachers or others intimately involved with the child. Baseline rating scales and periodic interval rating scales of their attitudes should be an essential part of the study.

B. Physician's attitude and role.

Factors that might be considered:

1. Experience in caring for children, especially treating their behavioral and emotional problems.

2. Previous experience using psychotropic drugs with adults or children, whether positive or negative. (It would be interesting to devise some studies of the same medications and similar populations, but with physicians with positive versus negative attitudes toward psychotropic drugs.)

3. Attitude toward psychotropic drugs, behavior modification, psychotherapy in relation to these problems.

4. Previous experience using psychotropic medication with own children or children of close friends or relatives and whether positive or negative.

5. Physicians own expectations from the study.

6. Why is he carrying out study? (What is in it for him?)

7. Orienting and training the physician in conducting the study.

a) Explanation of study to families. Will an attempt be made to achieve some consistency in these explanations in terms of purpose, design of study, use of placebos, warning re side effects etc? Will an effort be made to note time spent in orientation of subjects?

b) Procedure for follow-up visits. Consistency in questions asked, time spent with subjects.

c) Procedures for other than subject contacts. Discussion, explanation and time spent with teacher, nurse, etc.

d) Time interval between visits.

e) Length of study.

8. His attitude toward subject and family.

a) How long has he known them?

b) Previous experience (+ or -) with child.

c) His evaluation of parents and sibs.

d) Previous attempts in treating child.

9. Consistency of physician, subject contact. Same or different physician?

C. Child's attitude and role.

D. Parent's attitude and role.

E. Teacher's attitude and role.

Most of the following items will apply to all three of the above and should be considered in devising baseline and follow-up rating scales.

1. Severity and duration of child's symptoms.
2. Degree of stress caused by symptoms.
3. Previous experience with psychotropic medications.
 - a) What have heard from reading, TV, other parents, professionals?
 - b) Have they known a child treated with these medications--positive or negative effect?
 - c) Experience with own child and medication.
4. Expectations or hopes re effect of medication.
5. Fears re effects of medication.
6. Feelings re participating in study.
7. Understanding of why medication is being given.
8. Relationship with investigator.

Gastro intestinal and/or autonomic

Weight loss
Weight gain
Increased appetite
Decreased appetite
Mouth (mucosa, tongue, lip) dryness
Bad taste
Increased salivation
Stomach ache
Abdominal cramps
Nausea
Vomiting
Constipation
Diarrhea

Cardiovascular-respiratory and/or autonomic

Tachycardia
Bradycardia
Cardiac arrhythmias
Increased blood pressure
Decreased blood pressure
Chest pain
Dyspnea
Nasal Congestion
Nose bleeds
Fainting--blackouts

Genito--urinary and/or autonomic

Urinary frequency
Urinary retention
Bedwetting
Decreased bedwetting
Daytime incontinence
Painful urination

Ocular

Pupils--size
Retinal changes
Conjunctival injection, jaundice
Itching--tearing
Photosensitivity
Blurred vision
Extraocular muscle imbalance
Nystagmus

Skin and/or autonomic and/or idiosyncratic

Pallor
Flushing
Mottling
Sweating
Rash
Urticaria
Pruritis
Skin pigmentation
Jaundice
Purpura

Miscellaneous

Headache
Dizziness
Tiredness
Non-Specific somatic complaints

Side Effects--Behavioral

There may be some overlap in assessing behavioral side effects and target symptoms. Some of the behavioral side effects may be positive or negative and may or may not be target symptoms, but should be noted in these studies. Rating scales for parents, teachers and ? subject will be needed here.

Adverse Behavior Effects

Insomnia--Can't get to sleep
Restless sleep
Insufficient sleep
Nightmares
Drowsiness
Daydreaming
Apathy
Withdrawal
Fatigue
Sadness, unhappiness
Restlessness--motor
Goes from one thing to another
Irritability, jitteriness, tenseness
Decreased stress tolerance
Catastrophic reaction to stress
Catastrophic reaction to failure
Catastrophic reaction to new situations
Temper tantrums with frustration
Temper tantrums without frustration
Destructiveness
Negativism
Impersonal
Cruelty
Impulsiveness
Unpredictability
Fool hardiness
Mood swings, increased lability
Anxiety, fearfulness
Oversensitivity
Weepiness, crying spells
Memory lapses, impairment

Positive Behavior Effects

Improved sleep
More alert
More communicative
More energetic
Improved mood
Less restless
Finishes tasks
Calmer
Handles stress better
Handles failure better
Handles new situations better
More even tempered
More even tempered with frustration
Less destructive
More positive mood
More concerned with people around him
Plans ahead
Requires less supervision
More cautious
More even disposition
Less fearful, anxious
Improved memory

Adverse Behavior Effects (cont.)

Confusional states
Hallucinations
Perseveration
Repetitive motor activity--
 rocking, head banging

Positive Behavior Effects (cont.)

More aware of surroundings

More tractable

Summary

The following rating sheets may need to be devised for baseline and follow-up information relative to side effects:

1. Ascertaining actual medication intake. (Baseline information and periodic assessment.)
2. Physician's attitude and role
3. Child's attitude and role
4. Parent's attitude and role
5. Teacher's attitude and role
6. Side effects--physical (?Interval rating sheets for parents, too.)
7. Side effects--behavioral (interval rating sheets for parents, interval rating sheets for teacher)

✓ Methylphenolate	(Ritalin)
✓ Clonidine	Draver
✓ Chlorpromazine	(Thorazine)
✓ Thioridazine	(Mellaril)
✓ Diphenhydramine	(Benadryl)
✓ Imipramine	(Tofranil)
✓ Nortriptyline	(Aventyl)
✓ Perphenazine	(Trileptal) cyclic
✓ Trifluoperazine	(Stelazine) Anticholinergic
✓ Fluphenazine	(Prolixin)
✓ Mochlorpromazine	(Compazine)
✓ Chlorprothixene	(Taracten)
✓ Haloperidol	(Haldol)
✓ Amitriptyline	(Elavil)
Phenazine MDO	()
✓ Chlorhexidine	(Librium)
✓ Diazepam	(Valium)
✓ Meprobamate	(Miltomon)
✓ Meprobamate	(Cyfert)

Chlorpromazine	Tremor	Rigidity	Ataxia	Poor balance	Incoordination	Weakness	Atonia	Dystonic symptoms	Motor restlessness	Masked facies	Speech changes	Driveling	Parathesias	Seizure activity	Head hypertension	Weight loss	Weight gain	> appetite	< appetite	Mouth dryness	Bad taste	> salivation	Stomach ache	Abdominal cramps	Nausea	Vomiting	Constipation	Diarrhea
Thioridazine	X	X	X					X					X	X	X					X			X					
Fluphenazine							X	X																				
Perchlorazine							X	X																				
Chlorprothixene							X	X																				
Haloperidol								X																				
Amisulpride																			X									
Ziprasidone																				X								
Verapamil																												
Phenelzine																												
Moclobemide			X				X																					
Diazepam																												
Neurolept analgesia																												
Tufluprazine								X	X																			
Orphenazine								X																				
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												
Diaceprol																												

[illegible]

[illegible]

* reduces psychomotor excitement + disorganized
psychotic behavior.
** + ?? activating effect

Tranquillizers

Major

Phenothiazine derivatives

* Chlorpromazine (Thorazine) (30-1000 mgm) (0.6 mg/lb) } open chain
Promazine (Sparine) (30-1000 mgm) } ^{superior} dimethylamine
(weaker) + < toxic - ? higher incidence
Trifluoperazine (Vesprin) }
> + > toxic (20-200 mgm)

see separate page

Prochlorperazine (Compazine) < little +
> + > toxic for children
(5-200 mgm) 5x10x chlorpromazine

agranulocytosis
> chapyrindal effects
Instability
agitation
dyskinesia
less impaired children

Perphenazine (Trilafon) most toxic + ?? effective
> + > toxic 5x10x chlorpromazine (??)

Piperazine N (N)

** Tri fluperazine (Stelazine) < tolerated well by children
> + > toxic 20-100x chlorpromazine (1-80 mgm)
C < dysphoria may > alertness
and motor drive. Fresh

side chain
abstinent or
chry

Fluphenazine (Prelixin) - long acting
> + > toxic than (0.5-10 mgm)
100x potent

? reversible T wave changes

* Thioridazine (Mellaril) long acting
> toxic (some say < toxic) - life changes
(15-500 mgm) 0.6/lb accumulates in 3-4 da

Piperazine

thioxanthene derivatives

Chlorprothixene (Taractan) - like chlorpromazine
safe for children - inhibits psychomotor
control of fine motor activities
gross psychomotor

Rauwolfia Alkaloids

for severely schizophrenic only

Reserpine (Serpasil) - strong parasymp
(0.1-10 mgm) inhibitory

{ lethargy
mood
nightmares
Parkinsonism
convulsions
diarrhea
nasal congest.
↑ BP

Butyrophenones

Halo peridol (Haldol) still investigational
useful in Gilles de la Tourette's Syndrome
psychomotor agitation

{ EPS
transience

Tranquillizers

Major

Phenothiazine Derivatives - 1) schizophrenia, autism
2) hyperlinearity < destructive or aggressive behavior

Chlorpromazine (Thorazine)

depressed reticular system, brain stem
inhibits reamination of serotonin
interferes c nor epi → < symp. discharge
partly biotransformed - liver

? infertility

Side effects

sleepiness
weakness, apathy, chilliness
motor restlessness

tremors
torsion spasms } less in children
Parkinsonism }
seizures

rare { melanosis - skin
 - retina, cornea, lens
 dyskinesia

Toxicity

constipation
orthostatic hypotension
dermatitis - photosensitized
amenorrhea
urinary retention
fluid retention
weight gain
EKG changes

Rare

jaundice
aplastic anemia
agranulocytosis
asthma

Anti depressants

?? nse

Monamine Oxidase Inhibitors (MAOI) > nor epi
5 H-T
[rarely indicated in children] Phenelzine

~~Isopropyl (Marsalid)~~
very toxic

Don't use MAOI or
benzohazepine

Imine benzyl Derivatives

(tricyclic anti depressants)

Imipramine (Tofranil)
(10-200 mgm)

Nortriptyline (Aventyl)
(10-200 mgm)

Anticholinergic like side effect
dry mouth
constipation
tachycardia
blurred vision
drowsiness
urinary retention
loss of libido
rare agranulocytosis
coarse tremors
myoclonic spasms

like phenothiazines
onset of action is
slow - requires
several days to weeks to
establish drug effect.

amitriptyline (Elavil)

> drowsiness
rare convulsions

Minor Stimulants (Whitall - Mild Anti-depressants)

excitatory action - retic activating system

Amphetamines -

amphetamine (Benzedrine)

dextro " (Dexedrine)

Whitall (2.5 - 60.0 mgm)

Werner 0.1 mgm / lb

Mills & Co (2.5 - 40 mgm)

Methamphetamine (Methedrine)
(2.5 - 30 mgm)

mouth dryness
anorexia
wt loss
insomnia
> irritability
palpitation tachycardia
sweating
GI disturbances
stomach
tremor

Piperidine derivatives

Methyl phenidate (Ritalin)
(10 - 80 mgm)

Whitall

Werner

Mills & Co

0.1 mgm / lb

5 - 200 mgm (0.25 mgm / kilo $\Rightarrow$ 2 mgm / kilo)

acts on RAS
improves coord
marcapapay

agitation
insomnia
GI disturbance
occasional anorexia
rash
dizziness
chest pains
rare cardiac arrhythmias
- facial twitching, speech difficulty &
tongue & lip movements.

Tertiary Amine - ? acetylcholine precursor

Deanol (Deanol)
(25 - 300 mgm)

muscular tension
twitching
insomnia
headaches
pruritis
rash
constipation
mayt seizures

Magnesium Picolinate (Cylert)
? improves memory.

Tranquillizers

minor (cont)

Glycerol derivatives, propandiol derivatives

meprobamate (Miltom, Equenil)
? if better than phenobarb
(200-2400 mgm) (singes c withdrawal)

{
flou
K⁺
redsh
↓ BP
leucopenia
purpura
ataxia

Benzodiazepines act on limbic system, thalamus + hypothalamus
anti conv. action

> potent tranquillizers than above

chlordiazepoxide (Librium)
(10-300 mgm)

diazepam (Valium)
(2-40 mgm) useful w. status epilepticus

{
drowsiness + fatigue
ataxia
muscle weakness
hypotension
constipation
incontinence
rash
blood dyscrasias
edema
jaundice (rare)
drowsiness

withdrawal symptoms.
paradoxical resp reactions
confusion

Diphenmethane derivatives (Anticholinergic)

Diphenhydramine (Benadryl)
caution c seizures
(25-400 mgm)

Hydroxyzine HCl (Atarax, Vistaril)
Antihistamine
(20-1000 mgm)

{
drowsiness
[reverses dystonic syndrome caused by major tranquillizers]
dizziness
dry mouth
relieve over excitation

